Programme

  1. Home
  2. Programme

SPEAKERS

Ann-Lii (Andrew) Cheng

AFFILIATION:

National Taiwan University NTU Cancer Center, Taiwan, ROC

POSITION TITLE:

Chair Professor and President Emeritus

EDUCATION/TRAINING:

1973-1980

M.D., National Taiwan University, College of Medicine, Taipei, Taiwan, R.O.C.

1991-1994

Ph.D., Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine.

 

HONORS:

1997

「Outstanding Research Award」of Chinese Oncology  Society.

1998-1999

「Outstanding Research Award」of National Science Council, R.O.C..

1999

「Excellent Research Award」of Formosan Medical  Association, Taiwan, R.O.C..

1999

「Outstanding Medical Research Award」of the “Min-Tsai medical Fundation” 

1999

「Excellent Teacher Award」of National Taiwan University.  

2003



 

「Outstanding Clinical Teacher Award」of College of Medicine, National Taiwan University. 

2003-2005

「Outstanding Research Award」of National Science Council, R.O.C..

2003

「Excellent Teacher Award」of National Taiwan University. 

2004

「Excellent Teacher Award」of National Taiwan University. 

2007

「Excellent Teacher Award」of National Taiwan University. 

2007

Fellow, AAAS (American Association for the Advancement of Science)

2008.11

「Award for outstanding contributions for science and technology」from Executive Yuan (central administrative organ), Taiwan 


 

2009.9

Excellent Teacher Award」of National Taiwan University. 


 

2010.03

「Outstanding Research Award」of National Science Council, R.O.C..

2010.09

Excellent Teacher Award」of National Taiwan University. 

2010.12

Academy Award from Ministry of Education, Taiwan. 

2011.09

Excellent Teacher Award」of National Taiwan University.

2012.09

Excellent Teacher Award」of National Taiwan University.

2013.11

The National Professorship from Ministry of Education, Taiwan.

2017.7

President, APPLE (Asia Pacific Primary Liver Cancer Expert Meeting) Society 

2020.1

Blue Faery Award for Excellence in Liver Cancer Research
   

2020.6

NTU Distingished Chair Professor
   

2021.6

The Phi Tau Phi Scholastic Honor Society of the Republic of China,26th「Outstanding Research Award」

2021.11

4th Global Corporate Sustainability Forum, outstanding achievement award.

 

RESEARCH INTERESTS:

Dr. Ann-Lii Cheng is NTU Chair professor and President Emeritus of the NTU Cancer Center of National Taiwan University. Dr. Cheng is actively involved in basic and translational research of hepatocellular carcinoma and has contributed to all contemporary first-line treatment of advanced HCC.

PUBLICATIONS:

Selected publications in liver cancer

 

  1. Cheng AL*, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Lim HY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Ma N, Nicholas A, Wang Y, Li L, Zhu AX, Finn RS.  Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.  J Hepatol. 2022 Apr;76(4):862-873.

  2. Finn RS, Kudo M, Cheng AL, Wyrwicz L, Ngan RKC, Blanc JF, Baron AD, Vogel A, Ikeda M, Piscaglia F, Han KH, Qin S, Minoshima Y, Kanekiyo M, Ren M, Dairiki R, Tamai T, Dutcus CE, Ikezawa H, Funahashi Y, Evans TRJ.  Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study.  Clin Cancer Res. 2021 Sep 1;27(17):4848-4858.

  3. Hsu CL, Ou DL, Bai LY, Chen CW, Lin L, Huang SF, Cheng AL, Jeng YM, Hsu C.  Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma.  Liver Cancer 2021 Jul;10(4):346-359.

  4. Shen YC, Lee PC, Kuo YL, Wu WK, Chen CC, Lei CH, Yeh CP, Hsu C, Hsu CH, Lin ZZ, Shao YY, Lu LC, Liu TH, Chen CH, Wu MS, Huang YH, Cheng AL*.  An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma.  J Hepatocell Carcinoma  2021 Jul 24;8:809-822.

  5. Qin S, Ren Z, Feng YH, Yau T, Wang B, Zhao H, Bai Y, Gu S, Li L, Hernandez S, Xu DZ, Mulla S, Wang Y, Shao H, Cheng AL*  Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study.  Liver Cancer 2021 Jul;10(4):296-308.

  6. Ann-Lii Cheng*.  Pursuing efficacious systemic therapy for hepatocellular carcinoma.  Nat Rev Gastroenterol Hepatol. 2021 Feb;18(2):95-96.(review).

  7. Richard S. Finn, Shukui Qin, Masafumi Ikeda, Peter R. Galle, Michel Ducreux,  Tae-You Kim, Masatoshi Kudo, Valeriy Breder, Philippe Merle, Ahmed O. Kaseb, Daneng Li, Wendy Verret, Derek-Zhen Xu, Sairy Hernandez, Juan Liu, Chen Huang, Sohail Mulla, Yulei Wang, Ho Yeong Lim, Andrew X. Zhu, Ann-Lii Cheng*. Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020 May 14;382(20):1894-1905.

  8. de Bono J, Lin CC, Chen LT, Corral J, Michalarea V, Rihawi K, Ong M, Lee JH, Hsu CH, Yang JC, Shiah HS, Yen CJ, Anthoney A, Jove M, Buschke S, Fuertig R, Schmid U, Goeldner RG, Strelkowa N, Huang DC, Bogenrieder T, Twelves C, Cheng AL.  Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours.  Br J Cancer. 2020 Apr;122(9):1324-1332.

  9. Shen YC, Hsu CL, Jeng YM, Ho MC, Ho CM, Yeh CP, Yeh CY, Hsu MC, Hu RH, Cheng AL*.  Reliability of a single-region sample to evaluate tumor immune microenvironment in hepatocellular carcinoma. J Hepatol. 2020 Mar;72(3):489-497.

  10. Cheng AL* Hsu C, Chan SL, Choo SP, Kudo M.  Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J Hepatol. 2020 Feb;72(2):307-319.

  11. Nault JC, Cheng AL, Sangro B, Llovet JM. Milestones in the Pathogenesis and Management of Primary Liver Cancer.  J Hepatol. 2020 Feb;72(2):209-214.

  12. Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan SL, Knox J, Daniele B, Ebbinghaus SW, Chen E, Siegel AB, Zhu AX, Cheng AL; KEYNOTE-240 investigators. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol. 2020 Jan 20;38(3):193-202.

  13. Lu LC, Hsu C, Shao YY, Chao Y, Yen CJ, Shih IL, Hung YP, Chang CJ, Shen YC, Guo JC, Liu TH, Hsu CH, Cheng AL.  Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Liver Cancer. 2019 Nov;8(6):480-490.

  14. Liu TH, Shao YY, Lu LC, Shen YC, Hsu C, Lin ZZ, Hsu CH, Cheng AL*.  Considerations of heterogeneity in clinical trials for hepatocellular carcinoma.  Expert Rev Gastroenterol Hepatol. 2019 Jul;13(7):615-621.

  15. Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, Knox J, Daniele B, Webber AL, Ebbinghaus SW, Ma J, Siegel AB, Cheng AL, Kudo M; KEYNOTE-224 investigators.  Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.  Lancet Oncol. 2018 Jul;19(7):940-952.  Correction to Lancet Oncol 2018; 19: 940-52. Lancet Oncol. 2018 Sep;19(9):e440.

  16. Yen CJ, Kim TY, Feng YH, Chao Y, Lin DY, Ryoo BY, Huang DC, Schnell D, Hocke J, Loembé AB, Cheng AL*.  A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma.  Liver Cancer. 2018 May;7(2):165-178.

  17. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.  Lancet. 2018 Mar 24;391(10126):1163-1173

  18. Masatoshi Kudo, Ann-Lii Cheng, Joong-Won Park, Jae Hyung Park, Po-Chin Liang, Hisashi Hidaka, Namiki Izumi, Jeong Heo, Youn Jae Lee, I-Shyan Sheen,  Chang-Fang Chiu, Hitoshi Arioka, Satoshi Morita, Yasuaki Arai.  Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.  Lancet Gastroenterol Hepatol. 2018 Jan;3(1):37-46.

  19. Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.  Hepatol Int. 2017 Jul;11(4):317-370.

  20. Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G; RESORCE Investigators..  Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.  Lancet. 2017 Jan 7;389(10064):56-66.

  21. Lin HH, Feng WC, Lu LC, Shao YY, Hsu CH, Cheng AL.  Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.  Cancer Lett. 2016 Oct 10;381(1):58-66.

  22. Cheng AL*, Thongprasert S, Lim HY, Sukeepaisarnjaroen W, Yang TS, Wu CC, Chao Y, Chan SL, Kudo M, Ikeda M, Kang YK, Pan H, Numata K, Han G, Balsara B, Zhang Y, Rodriguez AM, Zhang Y, Wang Y, Poon RT. Randomized, Open-Label Phase 2 Study Comparing Frontline Dovitinib vs Sorafenib in Patients With Advanced Hepatocellular Carcinoma.  Hepatology. 2016 Sep;64(3):774-84.

  23. Li-Chun Lu, Chih-Hung Hsu, Chiun Hsu, Ann-Lii Cheng*.  Tumor hterogeneity in Hepatocellular Carcinoma: Facing the Challenges. Liver Cancer  2016;5:128–138 (Review)

  24. Cheng AL*, Kang YK, He AR, Lim HY, Ryoo BY, Hung CH, Sheen IS, Izumi N, Austin T, Wang Q, Greenberg J, Shiratori S, Beckman RA, Kudo M; Investigators’ Study Group.  Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study. J Hepatol. 2015 Oct;63(4):896-904.

  25. Ou DL, Chang CJ, Jeng YM, Lin YJ, Lin ZZ, Gandhi AK, Liao SC, Huang ZM, Hsu C, Cheng AL*.  Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma. J Gastroenterol Hepatol. 2014 Dec;29(12):2021-31.

  26. Lu LC, Cheng AL*, Poon RT.  Recent advances in the prevention of hepatocellular carcinoma recurrence.  Semin Liver Dis. 2014 Nov;34(4):427-34.

  27. Cheng AL, Amarapurkar D, Chao Y, Chen PJ, Geschwind JF, Goh KL, Han KH, Kudo M, Lee HC, Lee RC, Lesmana LA, Lim HY, Paik SW, Poon RT, Tan CK, Tanwandee T, Teng G, Park JW.  Re-evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel.  Liver Int. 2014 Feb;34(2):174-83.

  28. Hsu C, Tsou HH, Lin SJ, Wang MC, Yao M, Hwang WL, Kao WY, Chiu CF, Lin SF, Lin J, Chang CS, Tien HF, Liu TW, Chen PJ, Cheng AL*; Taiwan Cooperative Oncology Group. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study. Hepatology. 2014;59:2092-2100.

  29. Ou DL, Lee BS, Lin LI, Liou JY, Liao SC, Hsu C, Cheng AL*.  Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: the role of survivin.  Mol Cancer. 2014 Jan 3;13(1):2.

  30. Shao YY, Wu CH, Lu LC, Chan SY, Ma YY, Yen FC, Hsu CH, Cheng AL*. Prognosis of Patients with Advanced Hepatocellular Carcinoma Who Failed First-Line Systemic Therapy.  J Hepatol. 2014 Feb;60(2):313-8.

  31. Cheng AL*, Kang YK, Lin DY, Park JW, Kudo M, Qin S, Chung HC, Song X, Xu J, Poggi G, Omata M, Pitman Lowenthal S, Lanzalone S, Yang L, Lechuga MJ, Raymond E.  Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial.  J Clin Oncol. 2013 Nov 10;31(32):4067-75.

  32. Shao YY, Hsu CH, Cheng AL*.  Predictive Biomarkers of Antiangiogenic Therapy for Advanced Hepatocellular Carcinoma: Where Are We?  Liver Cancer. 2013 Apr;2(2):93-107. (Review).

  33. Shen YC, Ou DL, Hsu C, Lin KL, Chang CY, Lin CY, Liu SH, Cheng AL*. Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma. Br J Cancer. 2013 Jan 15;108(1):72-81.

  34. Hsu CH, Kang YK, Yang TS, Shun CT, Shao YY, Su WC, Sandoval-Tan J, Chiou TJ, Jin K, Hsu C, Cheng AL*.  Bevacizumab with Erlotinib as First-line Therapy in Asian Patients with Advanced Hepatocellular Carcinoma: A Multicenter Phase II Study.  Oncology. 2013 Jul 4;85(1):44-52.

  35. Park JW, Amarapurkar D, Chao Y, Chen PJ, Geschwind JF, Goh KL, Han KH, Kudo M, Lee HC, Lee RC, Lesmana LA, Lim HY, Paik SW, Poon RT, Tan CK, Tanwandee T, Teng G, Cheng AL*.  Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC).  Liver Int. 2013 Mar;33(3):327-37.

  36. Shao YY, Huang CC, Lin SD, Hsu CH, Cheng AL＊.  Serum Insulin-Like Growth Factor-1 Levels Predict Outcomes of Patients with Advanced Hepatocellular Carcinoma Receiving Antiangiogenic Therapy.  Clin Cancer Res. 2012 Jul 15;18(14):3992-7.

  37. Shen YC, Hsu C, Cheng CC, Hu FC, Cheng AL＊.  A critical evaluation of the preventive effect of antiviral therapy on the development of hepatocellular carcinoma in patients with chronic hepatitis C or B: a novel approach by using meta-regression.  Oncology. 2012;82(5):275-89.

  38. Cheng AL＊, Guan Z, Chen Z, Tsao CJ, Qin S, Kim JS, Yang TS, Tak WY, Pan H, Yu S, Xu J, Fang F, Zou J, Lentini G, Voliotis D, Kang YK. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia-Pacific trial.  Eur J Cancer. 2012 Jul;48(10):1452-65.

  39. Hsu C; Yang TS; Ho TI; Hsieh RK; Yu CW; Hwang WS; Hsieh TY; Huang WT; Chao Y; Meng R; Cheng AL＊. Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study.  J Hepatology. 2012;56:1097-1103.

  40. Han KH, Kudo M, Ye SL, Choi JY, Poon RT, Seong J, Park JW, Ichida T, Chung JW, Chow P, Cheng AL.  Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia.  Oncology. 2011;81 Suppl 1:158-64.

  41. Ou DL, Shen YC, Yu SL, Chen KF, Yeh PY, Fan HH, Feng WC, Wang CT, Lin LI, Hsu C, Cheng AL＊. Induction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res. 2010 Nov 15;70(22):9309-18.

  42. Shao YY, Lin ZZ, Hsu C, Shen YC, Hsu CH, Cheng AL. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer. 2010 Oct 1;116(19):4590-6.

  43. Shen YC, Hsu C, Cheng AL＊. Molecular targeted thearpy for advanced hepatocellular carcinoma: current status and future perspectives.  J Gastroenterol. 2010 Aug;45(8):794-807. (Review)

  44. Shen YC, Hsu C, Chen LT, Cheng CC, Hu FC, Cheng AL＊. Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach. J Hepatol. 2010 Jun;52(6):889-94.

  45. Hsu CH, Shen YC, Lin ZZ, Chen PJ, Shao YY, Ding YH, Hsu C, Cheng AL＊. Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. J Hepatol. 2010 Jul;53(1):126-31.

  46. Hsu CH, Yang TS, Hsu C, Toh HC, Epstein RJ, Hsiao LT, Chen PJ, Lin ZZ, Chao TY, Cheng AL＊. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma.  Br J Cancer. 2010 Mar 16;102(6):981-6.

  47. Chen KF, Yu HC, Liu TH, Lee SS, Chen PJ, Cheng AL＊.  Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. J Hepatol. 2010;52:88-95.

  48. Faivre S, Raymond E, Boucher E, Douillard J, Lim HY, Kim JS, Zappa M, Lanzalone S, Lin X, Deprimo S, Harmon C, Ruiz-Garcia A, Lechuga MJ, Cheng AL. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study.  Lancet Oncol. 2009 Aug;10(8):794-800.

  49. Ou DL, Shen YC, Yu SL, Lee WC, Yeh LC, Hsu C, Cheng AL